Maze Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Maze Therapeutics, Inc. (MAZE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income52.23-100.42-114.94
Depreciation & Amortization3.304.093.82
Stock Based Compensation9.658.756.74
Change in Working Capital-1.52-6.32-3.24
Change in Accounts Payable-0.200.40-3.78
Change in Other Working Capital-1.32-6.722.48
Other Operating Activities12.307.072.48
Net Cash from Operating Activities75.95-86.83-99.20
Investing Activities
Capital Expenditures-1.15-0.44-1.97
Acquisitions0.000.00-1.20
Purchases of Investments0.000.00-1.20
Net Cash from Investing Activities-1.15-0.44-3.17
Financing Activities
Debt Repayment24.480.000.00
Common Stock Issued68.370.210.15
Net Cash from Financing Activities92.8516.391.73
Summary
Net Change in Cash167.65-70.88-100.65
Cash at Beginning of Period30.25101.13201.77
Cash at End of Period197.9030.25101.13
Free Cash Flow74.81-87.27-101.17
Supplemental Disclosures
Income Taxes Paid1.230.000.00